Dorzagliatin is under clinical development by Hua Medicine Shanghai and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dorzagliatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Dorzagliatin overview
Dorzagliatin (Huatangning) is an anti-diabetic agent. It is formulated as tablets for oral route of administration. Huatangning is indicated to improve glycemic control in adults with type 2 diabetes and in both to improve blood glucose control for Type 2 diabetes (T2D) patients, as monotherapy for drug-naïve T2D patients, or in combination with metformin in metformin tolerated T2D patients to control blood glucose level.
Dorzagliatin is under development for the treatment of type II diabetes (T2D), type I diabetes(T1D) and diabetic nephropathy. The drug candidate is a fourth generation glucokinase activator compound. It is administered orally. The drug candidate acts by targeting glucokinase.
See Also:
Hua Medicine Shanghai overview
Hua Medicine Shanghai (Hua) is a Pharmaceutical company. It focuses on developing novel therapies for patients worldwide with unmet medical needs. The company strives to develop therapies for the treatment of diabetes. It works in collaboration with Covance Pharmaceutical R&D (Beijing) Co., Ltd; Shanghai MedKey Med-Tech Development Co., Ltd; Shanghai and Desano Pharmaceuticals Co., Ltd among others to develop and commercialize its product portfolio. Hua is headquartered in Pudong, shanghai, China.
For a complete picture of Dorzagliatin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
